Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.

Breast cancer research and treatment - 1 Apr 2022

Moore Grace M, Powell Simon N, Higginson Daniel S, Khan Atif J

Abstract excerpt

PURPOSE: Homologous recombination deficiency (HRD) is well characterized in triple-negative breast cancer (TNBC), but its prevalence in the hormone-receptor-positive breast cancer subtypes is not as clearly defined. It is estimated that around 50-60% of TNBC cases are deficient in HR. We sought to identify HRD cases in ER+/Her2- patients using various mutational HRD signatures. METHODS: We abstracted published...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Homologous Recombination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Oncogenes

Share to Prevalence

Share to Receptors, Estrogen

Share to Recombinational DNA Repair

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 35092538
DOI: 10.1007/s10549-022-06529-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.PMID 35092538Read ↗

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.Semantic proximity Read ↗

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.Semantic proximity Read ↗

The utility of homologous recombination deficiency biomarkers across cancer typesSemantic proximity Read ↗

Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read ↗

Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.Semantic proximity Read ↗

Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancerSemantic proximity Read ↗

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)Semantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.Semantic proximity Read ↗

Pan-cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read ↗

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancersSemantic proximity Read ↗

Homologous repair deficiency score for identifying breast cancers with defective DNA damage responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.